of this Current Report on Form 8-K (including Exhibit 99.1 hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings, except as expressly set forth by specific referen…

Chief Financial Officer — James Ahlers: The company hired a new Chief Financial Officer from outside the organization.

Other Events. On July 9, 2026, the Company issued a press release announcing the Private Placement. The full text of the press release is attached as Exhibit 99.1 hereto and is incorporated by reference herein. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, those regarding: the exp…

Entry into a Material Definitive Agreement. On July 9, 2026, Cue Biopharma, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with accredited investors (the “Investors”), including Cormorant Asset Management and Columbia Threadneedle Investments, pursuant to which the Company, in a private placement, agreed to issue and sell to the Investors an aggregate of (i) 1,418,071 shares of the Company’s common stock, par value $0.001 per share (the “Common St…

The Shares and Pre-Funded Warrants are being sold and, upon exercise of the Pre-Funded Warrants the Warrant Shares, will be issued without registration under the Securities Act of 1933, as amended (the “Securities Act”), in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as a transaction not involving a public offering and Rule 506 promulgated under the Securities Act as sales to accredited investors, and in reliance on similar exemptions under applicable state la…

The filing describes the grant of restricted stock units to employees and executive officers as part of a new incentive framework.

The filing is about the approval of a stock incentive plan, not a management change.

Director — Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen: Multiple directors resigned from the Board of Directors.

of this Current Report on Form 8-K (including Exhibit 99.1 hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings, except as expressly set forth by specific referen…

Other Events. On April 30, 2026, the Company issued a press release announcing, among other things, entry into the License Agreement. On April 30, 2026, the Company issued a press release announcing the Offering. The full text of each press release is attached as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K and incorporated herein by reference. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains forward-looking state…

Entry into a Material Definitive Agreement. Ascendant Health Sciences Ltd. License Transaction License Agreement On April 30, 2026, Cue Biopharma, Inc. (the “Company”) entered into a License Agreement (the “License Agreement”) with Ascendant Health Sciences Ltd., a Cayman Limited Company (the “Licensor”). Pursuant to the License Agreement and subject to certain rights retained by the Licensor, the Licensor granted the Company: (1) the exclusive and sublicensable rights to develop, manufacture…

President and Chief Executive Officer — Dr. Shao-Lee Lin: Dr. Shao-Lee Lin was appointed as the President and Chief Executive Officer, succeeding Lucinda Warren.

Based in part upon the representations of the Licensor in the Purchase Agreement, the offering and sale of the Licensor Securities will be exempt from registration under Rule 903 of Regulation S promulgated under the Securities Act. The Licensor Securities have not been registered under the Securities Act or any state securities laws, and the Licensor Securities may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from the registration re…

Material Modification to Rights of Security Holders. To the extent required by

Other Events On April 1, 2026, Cue Biopharma, Inc. (the “Company”) received notice from Boehringer Ingelheim that Boehringer Ingelheim had approved selection of its first compound for lead optimization under the Collaboration and License Agreement entered into with Boehringer Ingelheim on April 10, 2025 for the research, development and commercialization of differentiated B cell depletion molecules, including the Company’s CUE-501 product candidate. This preclinical milestone event triggers a…

President and Chief Executive Officer — Usman Azam: Dr. Usman Azam resigned as President and Chief Executive Officer, marking a significant departure.

Results of Operations and Financial Condition. On March 16, 2026, Cue Biopharma, Inc. issued a press release announcing financial results for the quarter and year ended December 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Current Report on Form 8-K (including Exhibit 99.1 hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Excha…

Chief Financial and Business Officer — Lucinda Warren: Ms. Lucinda Warren was promoted to Chief Financial and Business Officer.

Entry into a Material Definitive Agreement. On December 19, 2025, Cue Biopharma, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with H.C. Wainwright & Co., LLC, as representative of the several underwriters named therein (collectively, the “Underwriters”), relating to an underwritten public offering of (i) 12,500,000 shares (the “Firm Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”), and accompanying common sto…

Other Events. The full text of the press release announcing the pricing of the underwritten public offering on December 19, 2025 is attached as Exhibit 99.1 hereto and is incorporated herein by reference. Cash Runway Based upon the Company’s current plans and forecasted expenses, the Company estimates that the net proceeds from the underwritten offering, together with the Company’s existing cash, cash equivalents and marketable securities, including the $5.0 million in upfront payments the Co…

Chief Medical Officer — Matteo Levisetti: Dr. Levisetti's employment with the Company will terminate effective November 28, 2025.

Results of Operations and Financial Condition. On November 12, 2025, Cue Biopharma, Inc. issued a press release announcing financial results for the quarter ended September 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Current Report on Form 8-K (including Exhibit 99.1 hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange A…

Entry into a Material Definitive Agreement. On November 6, 2025, ImmunoScape Pte. Ltd. (“IMSCP”) exercised its option (the “Option”) to obtain licenses to research, develop and commercialize molecules from Cue Biopharma, Inc.’s (the “Company”) CUE-100 Series, including CUE-101 and CUE-102, subject to certain exclusions (the licensed series of molecules, the “Licensed Program”), for all oncology indications pursuant to a Collaboration and License Agreement, effective November 6, 2025, between…

President and Chief Executive Officer — Usman Azam: Dr. Usman Azam was appointed as President and Chief Executive Officer, succeeding Daniel R. Passeri.

Results of Operations and Financial Condition. On August 12, 2025, Cue Biopharma, Inc. issued a press release announcing financial results for the quarter ended June 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Current Report on Form 8-K (including Exhibit 99.1 hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), o…